Breast Health

COVID-19

Cervical Health 

Contraception

Curbside Consults

Dermatology

Drug Pipeline News

Endometriosis

Genetic Testing

Gynecologic Oncology

Gynecology

Fetal Imaging

Abnormal Obstetrical Ultrasound

Ultrasound

Women's Imaging

Breast Imaging

Women's Ultrasound

Imaging

Infertility

LARC

Legally Speaking

Life Transitions

Malpractice

Menopause

Mental Health

Noninvasive Prenatal Testing

Obstetrics

Opinion

Osteoporosis

Pediatrics

Practice Management

Pregnancy and Birth

Sexual Health

Sexually Transmitted Infections

Surgery

Technology

Urology

Uterine Fibroids

Vulvovaginal Disease

Well Woman

About

News

Media

Podcasts

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Videos

Conferences

Conference Coverage

Conference Listing

Publications

Contemporary OB/GYN® Journal

Digital Supplements

CME/CE

Resources

Physician Fact Sheets

Interactive Tools

Supplements and Featured Publications

Subscribe

Partnerships

 and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

 You can reach her at mpetronelli@mjhlifesciences.com.

Articles

Check out the top conferences happening in the second quarter of 2025.

3 conferences to watch in Q2 2025

The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.

FDA approves Visby’s test for at-home STI identification

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Contemporary OB/GYN week in review: Gepotidacin approval, placebo efficacy, and more

The 2025 Canadian Postpartum Guidelines recommend at least 120 minutes of weekly exercise, daily pelvic floor training, and improved sleep hygiene to enhance maternal and infant health.

Experts reveal new exercise guidelines for postpartum health benefits

Advertise

Contact Us

Job Board

Terms of Use

Privacy Policy

Do Not Sell My Personal Information

Contemporary OB/GYN

Facebook

LinkedIn

RSS Feed

Spotlight

A Psychedelic to Treat Postpartum Depression?

CMV: In the Know

RSV Roundtable

STIs

Supplement: Closing the Gap in Cervical Cancer Screening

Vaginismus: Managing a Misunderstood and Underdiagnosed Condition

Why vNOTES Make Sense for My Patients

1rem

Authors

Ryan Haumschild, PharmD, MS, MBA, CPEL, is vice president of pharmacy at Emory Healthcare and Winship Cancer Institute.

Ryan Haumschild, PharmD, MS, MBA, CPEL, explains the impact recently FDA-approved gepotidacin will have on uncomplicated UTIs and what this means in terms of antibiotic stewardship. 

How gepotidacin offers new option for uncomplicated UTIs, with Ryan Haumschild, PharmD

What is your diagnosis based on these images of the ovary?

Challenge your diagnostic skills with this image quiz: Is this ovarian lesion cystic in nature or something else?

Image IQ: Ovarian Cyst or Something Else?

A 27-year-old woman presents with an 18-month history of vulvar irritation. She is otherwise healthy except for episodes of depression. She has tried multiple agents for her condition including topical steroids, Vagisil, antibiotics, and fluconazole. She used oral steroids but developed knee pain. Tacrolimus has not helped. A biopsy revealed lichen simplex chronicus. Immunofluorescent studies were negative.

A 27-year-old woman presents with an 18-month history of vulvar irritation. She has tried multiple agents for her condition including topical steroids, Vagisil, antibiotics, and fluconazole without relief. What's your diagnosis?

Vulvar irritation in a 27-year-old woman

This middle aged patient complained of polymenorrhea and pelvic pain. Transvaginal images are shown below. What is your diagnosis?

There is a clearly defined rounded mass just below the endometrial stripe of the uterus. The endometrium itself appears normal in thickness ruling out hyperplasia.The mass is within the uterine fundus and body ruling out a cervical mass.

Clinical

Daily Dx: Polymenorrhea and Pelvic Pain

Saying "obstetrician-gynecologist" is a mouthful for most people, and it's probably the most abbreviated specialty in medicine, both spoken and written. However, there doesn't seem to be a consensus on how to pronounce OB-GYN. First, is it the two-syllable "O-B" or the monosyllabic "Ob"? Second, is it "gin" or "gyne" (like "Lyme")? I wonder if you have a preference. I know I do.

Almost nobody says "obstetrician-gynecologist" when speaking about these specialist physicians. But what's the "correct" way to pronounce OB/GYN?

Is It Ob-Gin or Ob-Gyne?

What’s your diagnosis in this 12-week pregnancy?

Challenge your diagnostic skills: Can you identify this anomaly?

Image IQ: A 12-Week Fetus

Stress urinary incontinence

Wanda Filer, MD, MBA FAAFP, from Pelvital, discussed barriers to stress urinary incontinence (SUI) treatment, and how OB-GYNs may address these issues.

SUI is a widespread condition affecting many women, with urinary incontinence in general impacting approximately 62% of US women. Among these cases, stress urinary incontinence is the most common. 

Despite its prevalence, many women feel embarrassed or reluctant to discuss their symptoms with a health care provider. There is a cultural normalization of the condition, as women are frequently exposed to advertisements for incontinence pads, leading them to believe they should manage the issue rather than seek treatment. As a result, most women do not bring up their symptoms to a clinician for at least 10 years, prolonging their discomfort and limiting their access to effective solutions.

One of the main barriers to treatment is the lack of awareness among both patients and health care providers. Many clinicians may only suggest Kegel exercises without exploring other available treatments, leaving patients with limited options. According to Filer, there is a significant opportunity for improvement in addressing SUI from both the patient and clinician perspectives. Screening for urinary incontinence is essential, particularly among postpartum women and older women, who are at a higher risk of experiencing the condition. Studies show that 1 in 3 postpartum women develop urinary incontinence within 3 months after childbirth, and many continue to experience symptoms years later.

To ensure patients receive proper care, Filer urged OB-GYNs and primary care providers to actively screen for urinary incontinence and educate women about available treatment options. One promising treatment discussed by Filer was Flyte, a device that utilizes mechanotherapy to provide results comparable to surgery. This at-home treatment requires only 5 minutes of use per day for 6 weeks, making it a convenient and effective solution for patients.

By integrating routine screening and increasing awareness of treatment options, health care providers can help women overcome the stigma surrounding SUI and access the care they need to improve their quality of life.

This video is part 1 of a 2-part series. Click 

Pelvital announces pivotal article highlighting efficacy of transvaginal mechanotherapy as first-line treatment for stress urinary incontinence. Pelvital. February 12, 2025. Accessed March 14, 2025. https://www.prweb.com/releases/pelvital-announces-pivotal-article-highlighting-efficacy-of-transvaginal-mechanotherapy-as-first-line-treatment-for-stress-urinary-incontinence-302374521.html.

Many women struggle with stress urinary incontinence but delay treatment because of embarrassment and lack of awareness, highlighting a need for screening and innovative treatments.

Ryan Haumschild, PharmD, MS, MBA, CPEL

Articles

Latest Updated Articles